Author:
Gu Jue,Zhao Yamin,Ben Yue,Zhang Siming,Hua Liqi,He Songnian,Liu Ruizi,Chen Xu,Sheng Hongzhuan
Funder
Nantong Municipal Health Commission
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Wang, L. et al. Assessment of reversibility in pulmonary hypertension related to congenital heart disease by using biomarkers and clinical features. Congenit. Heart Dis. 17(1), 87–97 (2022).
2. Park, J.-S. et al. Factors affecting the genetic diagnostic rate in congenital heart disease. Congenit. Heart Dis. 17(6), 653–673 (2022).
3. Yusuf, S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. Lancet 395(10226), 795–808 (2020).
4. McCarty, M. F. Nutraceutical, dietary, and lifestyle options for prevention and treatment of ventricular hypertrophy and heart failure. Int. J. Mol. Sci. 22(7), 3321 (2021).
5. Xin, L. et al. Integrative expression analyses revealed potential biomarkers in hypertrophic cardiomyopathy. J. Biol. Regul. Homeost. Agents 37(6), 3141–3150 (2023).